B+
Bull case
25%
Probability
Target price
$470.00
Analysis reference price unavailable
Analysis 2026-07-20 · RankAlpha Sentiment Codex
ELV
Elevance HealthCNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$410.00
Analysis reference price unavailable
Analysis 2026-07-20 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$300.00
Analysis reference price unavailable
Analysis 2026-07-20 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-20
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+56.6
Score
AI commentary
News tone is mixed: the company source confirms a Q2 beat and higher guidance [#SEC-8K-2026-07-15], while stored coverage highlights an approximately 8.5% selloff centered on Medicaid concerns [#PR-EARNINGS-2026-07-17]. Social coverage and analyst revision data are unavailable, so the positive deterministic prior is treated as a tentative recovery signal rather than confirmation of a durable re-rating. The peer comparison is limited to two relevant payer/service comparators because the remaining packet candidates are device, distributor, or provider businesses rather than direct ELV peers.
RankAlpha Sentiment Codex - 2026-07-20
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-07-31catalystPost-earnings digestion of a strong print versus Medicaid concernsMedium impact
Elevance reported Q2 adjusted EPS of $7.45, raised FY2026 adjusted EPS guidance to at least $27.00, and raised operating cash-flow guidance to at least $6.0 billion [#SEC-8K-2026-07-15] [#8-K-2026-07-15]. Stored post-earnings coverage reported an approximately 8.5% share-price decline as investors focused on Medicaid weakness [#PR-EARNINGS-2026-07-17].
2027-07-15eventMedicaid remediation and market-exit executionHigh impact
Stored earnings context reports a FY2026 Medicaid operating-margin outlook of -1.75%, an agreement to exit the D.C. Medicaid market, and possible exits from additional markets over the next 12–18 months [#PR-EARNINGS-2026-07-17]. Evidence of improving cost performance or a credible remediation path could support recovery; further deterioration would pressure the shares.
2027-12-31catalyst2027 earnings-growth recoveryHigh impact
Management stated confidence in returning to at least 12% adjusted EPS growth in 2027, supported by medical-cost management, operating investments, and Carelon capabilities [#SEC-8K-2026-07-15]. Delivery depends on stabilizing government-business medical trends and executing the Medicaid reset.
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology